Steroid target tissues regulate the local level of steroid hormone that can bind and trans-activate nuclear receptors (a process known as intracrine modulation). This pre-receptor regulation can be achieved by hydroxysteroid dehydrogenases (HSDs). For each sex hormone there is a pair of HSD isoforms which act either as reductases or oxidases to convert potent steroid hormones into their cognate inactive metabolites, or vice-versa. In this manner, HSDs can function as molecular switches to regulate steroid hormone action. Because these HSDs show tissue-speci®c expression, inhibitors of these enzymes are predicted to cause tissue-speci®c responses to steroid hormones. These inhibitors would represent a new class of therapeutics called`selective intracrine modulators' (SIMs). SIMs are expected to have the same tissue-speci®c effects as selective steroid receptor modulators but a different mode of action as their effects are enzyme-and not receptor-mediated. HSDs responsible for these interconversions belong to two protein superfamilies: the short-chain dehydrogenases/reductases; and the aldo-keto reductases. Crystal structures exist for HSDs in both families, making rational design of SIMs a reality. Broad-based criteria have been established which must be ful®lled to validate each HSD isoform as a potential SIM target.
Introduction
Steroid hormones exert their action by binding to soluble nuclear receptors (Carcon-Jurica et al., 1990) . Once bound, the steroid hormone±receptor complex dissociates from chaperone proteins and dimerizes. The ligand-bound dimeric receptor then binds to steroid hormone-responsive elements on the 5¢-¯anking (promoter) region of steroid hormone-responsive genes to cause a change in gene transcription; this process is known as transactivation ( Figure 1 ) (Carcon-Jurica et al., 1990; Landers and Spelsberg, 1992; Truss and Beato, 1993) . Agonist action was viewed as causing gene transcription by mimicking the action of the endogenous steroid ligand, while antagonist action was viewed as a competition with the agonist resulting in a blockade of gene transcription. This view has been supplanted by the concept that ligands alter the conformation of the receptor (Brzozowksi et al., 1997; Wijayaratne et al., 1999) to recruit tissue-speci®c coactivators (CA; e.g., SRC-1/NcoA-1) and co-repressors (CR; e.g. NcoR, SMRT) leading to a graded response (Klinge, 2000; McDonnell, 2000) . Thus, antagonists are now often referred to as selective steroid hormone receptor modulators because, depending on the tissue distribution of CA and CR, steroid receptor ligands may act as agonists in one tissue and antagonists in another. For example, tamoxifen will act as an estrogen receptor agonist in the uterus and bone, but as an antagonist in the breast (Dhringa, 1999; Jones et al., 1999; Tobias, 1999) . Tamoxifen and its successor raloxifene are now referred to as selective estrogen receptor modulators (SERMs) (Ibrahim and Hortobagyi, 1999) .
Steroid target tissues also modulate steroid action at the prereceptor level by regulating the amount of steroid hormone ligand available for receptor occupancy. This review will focus on the pre-receptor regulation of steroid hormone action, where ligand access to the receptor in target tissues is under enzyme control. The enzymes that are the focal point of this article are the hydroxysteroid dehydrogenases (HSDs) (Penning, 1997) .
HSDs play a pivotal role in the local production of steroid hormones in target tissues (intracrine modulation) (Labrie et al., 2000) . For every sex hormone it is hypothesized that a pair of HSDs exist which will either convert a potent hormone into its cognate inactive metabolite, or vice-versa. HSDs often catalyse stereoselective reactions at speci®c positions of the steroid so that for each sex hormone there is an isoform that will either inactivate a hormone or produce an active ligand. This is achieved either by the reduction of a steroid ketone to a steroid alcohol (reductase activity) or by the oxidation of a steroid alcohol to a steroid ketone (oxidase activity). The reductive and oxidase activities of HSDs permit isoforms to function as molecular switches and turn receptor ligand occupancy`on' or`off'.
For example, the reductase responsible for the conversion of estrone (a weak estrogen) to 17b-estradiol (a potent estrogen) is the estrogenic type 1 17b-HSD and is the`on' switch for the estrogen receptor (ER). The oxidase activities responsible for the reverse reaction and the inactivation of 17b-estradiol are the type 2 and type 4 17b-HSDs, and these function as the`off' switch for the ER (Figure 2 ). Thus, the activity of these 17b-HSD isoforms may regulate the ligand occupancy of ERa and ERb and their transactivation in estrogen target tissues (Wu et al., 1993; Andersson, 1995; Labrie et al., 1997; . Because HSD isoforms show tissue-speci®c expression and control intracrine levels of steroid hormones, isoform-speci®c HSD inhibitors will act as selective intracrine modulators (SIMs). It is likely that SERMs and SIMs will have similar pharmacological pro®les but different mechanisms of action. This review will also address routes to the development of SIMs.
Intracrine formation of steroid hormones
The intracrine formation of steroid hormones is of relevance in the aetiology of steroid-dependent breast and prostate cancer (Labrie et al., 1997) . Breast cancer is a disease that predominates in postmenopausal women. In these women the production of estrogens no longer takes place in the ovary, but occurs locally. A number of enzymes play a key role in the local production of 17b-estradiol (the most potent natural estrogen) in the breast. Dehydroepiandrosterone (DHEA) from the adrenal gland can be converted to D 4 -androstene-3,17-dione by 3b-HSD/ketosteroid isomerase (KSI) which is aromatized by cytochrome P450 aromatase (CYP arom) to yield estrone. Much of this estrone can be stored locally in the breast as estrone sulphate, and the release of free estrone is catalysed by estrogen sulphatase (Reed et al., 1996) . However, once free estrone (a weak estrogen) is formed it must be reduced to 17b-estradiol (a potent estrogen), and this reaction is catalysed by the estrogenic type 1 17b-HSD.
In parallel, androgen-dependent prostate cancer is a disease of the ageing male. Although Leydig cell testosterone biosynthesis wanes with age, circulating testosterone is produced in suf®cient amounts so that the prostate still synthesizes 5a-dihydrotestosterone (5a-DHT; the most potent androgen) from circulating testosterone via 5a-reductase type 2. However, the dependence on the local production of androgens becomes evident when hormonal ablative treatments for this disease are considered. Following castration, the prostate maintains its ability to produce androgens locally. In this situation, adrenal dihydroepiandrosterone (DHEA) becomes the principal source of androgens in the prostate (Labrie et al., 2000) . DHEA is converted to 5a-DHT via the concerted action of 3b-HSD/KSI, type 5 17b-HSD and 5a-reductase type 2 (Labrie et al., 1997) .
Following treatment with ®nasteride (a 5a-reductase type 2 inhibitor), prostatic 5a-DHT levels are suppressed by only 80%, indicating that another source of 5a-DHT is available (Gormley, 1996) . This source may be via the so-called back-reaction in which 5a-androstane-3a,17b-diol (3a-diol) is oxidized by 3a-HSD isoforms to yield 5a-DHT (Horst et al., 1975; Walsh and Wilson, 1976; McDermott et al., 1978) . In this sequence, the source of 3a-diol is likely to arise from the hepatic metabolism of C19-steroids. Thus, in prostate disease the impact of type 5 17b-HSD and oxidative 3a-HSD isoforms may be important in sustaining 5a-DHT levels. Thus, in two principal steroid hormonedependent cancers the local formation of potent steroid hormones by HSDs may play a key role in regulating receptor response.
Enzymes that control ligand access to steroid receptors
Enzymes other than HSDs can play important roles in controlling ligand access to steroid receptors. The importance of aromatase in making estrogens has been stressed. Similarly, 5a-and 5b-reductases can also play an important role by reducing the a,bunsaturated ketone present in the A-ring of most steroid hormones to yield the 5a-and 5b-reduced products. Furthermore, the action of steroid sulphatases (Reed et al., 1996) and steroid sulphotransferases (Falany et al., 1993; Luu-The et al., 1996) can affect the balance of active and inactive hormone available. The former will release steroids from their inactive conjugates, while the latter will eliminate the active hormone by conjugation in the presence of the sulphate donor phosphoadenosine-phosphosulphate.
However, the HSDs hold the greatest promise as drug targets. This is because the ®eld has matured to identify the discrete HSD isoforms responsible for the formation of active androgens, estrogens and progestins and their elimination in target tissues. Crystal structures also exist for several of the important HSDs, making rational approaches to inhibitor design feasible. An additional advantage is that HSDs work as discrete entities whereas steroid receptors work in concert with a multiprotein complex that contains CA and CR. At the last count there were in excess of 50 CA and CR for the ERa alone (Klinge, 2000) , suggesting that the rational targeting of these multi-protein complexes will be more dif®cult.
HSDs and pre-receptor regulation

11b-HSDs as prototypic SIM-targets
The differential effects of the human 11b-HSD isoforms provides a compelling example of how HSD isoforms regulate steroid hormone action at the pre-receptor level (Funder et al., 1988) . It is described here because this is a prototypic example of how HSDs can regulate steroid hormone response. It is likely that HSD isoforms involved in sex hormone interconversion will have similar properties. 11b-HSD type 2 functions as an NAD + -dependent 11b-oxidase to convert the potent glucocorticoid (cortisol) to the inactive glucocorticoid (cortisone) (Stewart and Whorwood, 1994) (Figure 2 ). Importantly, cortisol has high af®nity for either the glucocorticoid receptor or the mineralocorticoid receptor, and if it were not for the action of this enzyme the mineralocorticoid receptor would be¯ooded with excess cortisol. The protection of the mineralocorticoid receptor is achieved by discrete localization of the 11b-HSD type 2 isoform to the renal tubules, where it is co-expressed with the mineralocorticoid receptor (Rundle et al., 1989; Mercer and Krozowski, 1992; Albiston et al., 1994) . This ensures that the receptor will respond only to¯uctuating levels of aldosterone. Inherited de®ciencies of 11b-HSD type 2 (Mune et al., 1995; Obeyesekere et al., 1995; Wilson et al., 1995a; , or 11b-HSD type 2 inhibitors derived from liquorice (glycerrhetinic acid), can cause an apparent mineralocorticoid excess (AME) syndrome (Stewart et al., 1987; Monder et al., 1989) , thereby demonstrating the physiological signi®cance of this isoform in regulating steroid receptor occupancy. The importance of the 11b-HSD type 2 enzyme in regulating the mineralocorticoid receptor has since been con®rmed in 11b-HSD type 2 null mice which had a phenotype characteristic of AME . The ability of glycerrhetinic acid to mimic AME implies that this agent would represent a founder SIM.
In contrast, the 11b-HSD type 1 enzyme catalyses the reverse reaction. It acts predominantly as an NADPH-dependent 11-ketosteroid reductase and converts cortisone to cortisol, but may also act as a`local-ampli®er' of glucocorticoid action (Seckl and Walker, 2001 ). 11b-HSD type 1 is expressed in adipose tissue and in liver where it can regulate occupancy of the glucocorticoid receptor (Bujalska et al., 2002) . Transgenic mice overexpressing 11b-HSD type 1 in adipose tissue develop visceral obesity (Masuzaki et al., 2001) , while 11b-HSD type 1 null-mice have an improved lipid pro®le, hepatic insulin sensitization, and a potentially atheroprotective phenotype Figure 2 . Short-chain dehydrogenases/reductases (SDRs) that control ligand occupancy of steroid receptors. 11-cis-retinol DH = 11-cis retinol dehydrogenase; RoDH = RoDH, 3a-HSD-like dehydrogenase. . These studies emphasize the importance of this enzyme in controlling local cortisol action at the prereceptor level. Thus, in the case of 11b-HSD there are two isoforms: one which acts as an oxidase to eliminate active hormone; and the other which acts as a reductase to generate active hormone. It is hypothesized that the ability of HSDs to function as molecular switches and turn receptor occupancỳ on' and`off' will apply to those HSDs that interconvert sex steroid hormones.
HSD isoforms implicated in the regulation of sex steroid hormone receptors
HSDs that interconvert sex steroid hormones are the 3a-, 17b-and 20a-HSDs. Of these, 3a-HSD isoforms may regulate ligand access to the androgen receptor (AR) (Taurog et al., 1975; Jacobi and Wilson, 1976; Jacobi et al., 1977; Biswas and Russell, 1997) . 5a-DHT (a potent androgen; K d = 10± 11 M for the AR) is converted by 3-ketosteroid reductases to 3a-diol (a weak androgen; K d = 10 ±6 M for the AR) (Liao et al., 1973) . Candidate enzymes that can catalyse this reaction are the type 2 and type 3 3a-HSD (Figure 3 ). By contrast, 3a-hydroxysteroid oxidases can convert 3a-diol back to 5a-DHT. Candidate enzymes for this back-reaction are the type 3 3a-HSD, 11-cis-retinol dehydrogenase (11-cis-retinol DH) and RoDH/3a-HSD (Biswas and Russell, 1997; Penning et al., 2000; Chetyrkin et al., 2001; Huang and Lu-The, 2001a; .
Ligand occupancy of the AR may also be controlled by the type 5 17b-HSD which acts as a 17-ketosteroid reductase and converts D 4 -androstene-3,17-dione to testosterone Lin et al., 1997) and by the type 2 and type 4 17b-HSD that act as a 17b-hydroxysteroid oxidase and oxidize testosterone back to D 4 -androstene-3,17-dione (Wu et al., 1993; Andersson, 1995; Adamski et al., 1995) . The current view is that the type 3 17b-HSD, which reduces D 4 -androstene-3,17-dione to testosterone is not involved in regulating ligand occupancy of the AR in target tissues since it is Leydig cell-speci®c.
Similarly, ligand occupancy of estrogen receptor (ER)a will be regulated by the type 1 and type 5 17b-HSD which act as 17-ketosteroid reductases and convert estrone to 17b-estradiol (Peltoketo et al., 1988; Labrie et al., 1994; 1997; Penning et al., 2000) and by type 2 and type 4 17b-HSD which act as 17b-hydroxysteroid oxidases and oxidize 17b-estradiol back to estrone (Peltoketo et al., 1999) (Figures 2 and 3) . Recently, 5a-androstane-3b,17b-diol (3b-diol) was identi®ed as a ligand for ERb (Weihua et al., 2002) ; here, the occupancy of this receptor may be governed by 3b-HSD isoforms. 3-Ketosteroid reductases will reduce 5a-DHT to 3b-diol, and 3b-hydroxysteroid oxidases will convert 3b-diol back to 5a-DHT. Whether the classical type 1 and type 2 3b-HSD/ketosteroid isomerase (KSI)s catalyse these reactions in target cells, or whether other 3b-HSD isoforms are responsible for these reactions, remains to be determined.
The ligand occupancy of the progesterone receptor (PR) will be regulated by 20-ketosteroid reductase which will reduce progesterone (a potent progestin) to 20a-hydroxyprogesterone (a weak progestin). The enzymes responsible are human 20a(3a)-HSD (Burczynski et al., 1998; Penning et al., 2000; Zhang et al., 2000) and type 5 17b-HSD which has strong 20a-HSD activity (Dufort et al., 1999) . The 20a-hydroxysteroid oxidase responsible for the reverse reaction may be type 2 17b-HSD (Wu et al., 1993) . Each of these HSDs and their classi®cation into protein superfamilies are shown in Table I . Thus, for each sex hormone there emerge pairs of HSDs that control ligand access to the androgen receptor (AR), ER and PR.
HSDs belong to two protein superfamilies: the SDRs and AKRs
HSDs implicated in controlling ligand access to steroid receptors belong to two protein superfamilies (Jornvall et al., 1995; Penning, 1997) . The short-chain dehydrogenase/reductase (SDR) family consists of the 11b-HSDs which control ligand access to the mineralo-and glucocorticoid receptors and most of the 17b-HSD isoforms which may control ligand access to the AR and ER (Peltoketo et al., 1999) . There are currently 11 human 17b-HSD isoforms of which the type 1 and type 3 are the major reductive isoforms (Peltoketo et al., 1999) . The type 1 17b-HSD is also known as the estrogenic 17b-HSD since its principal activity is to reduce estrone to 17b-estradiol (Labrie et al., 1997; Peltoketo et al., 1999) . By contrast, the type 3 17b-HSD is known as the androgenic 17b-HSD and is a Leydig cell-speci®c enzyme which catalyses the reduction of D 4 -androstene-3,17-dione to testosterone . Its gene is mutated in 17KSR3 de®ciency, a condition that leads to pseudohermaphroditism, which underscores its importance in the production of testosterone in the testis (Geissler et al., 1994; Andersson et al., 1996) . Because of its discrete localization it is unlikely to synthesize testosterone in target tissues for the AR. This task is performed by the type 5 17b-HSD which is an aldo-keto reductase (AKR1C3) Dufort et al., 1999) .
The SDRs also contain the type 2 and type 4 17b-HSDs which are the major oxidative enzymes that inactivate testosterone and 17b-estradiol by forming D 4 -androstene-3,17-dione and estrone respectively (Adamski et al., 1995; Andersson et al., 1995) . These enzymes will deprive the AR and ER of their ligands. Of these enzymes, the type 2 may be the principal activity since the type 4 also catalysed 3-hydroxyacyl-CoA dehydrogenase activity and may function as a sterol-carrier protein (Adamski et al., 1995) .
The AKR gene superfamily contains many of the 3a-HSD and 20a-HSD isoforms (Jez et al., 1997a; . The human AKR1C family contains four human 3a-HSD isoforms (AKR1C1±AKR1C4) of interest that display varying ratios of 3-, 17-and 20-ketosteroid reductase activity and varying ratios of 3a-, 17b-and 20a-hydroxysteroid oxidase activity. This suggests that they may regulate ligand access to the AR, ER and PR respectively (see Table I ).
Members of the SDR and AKR superfamilies are easy to distinguish one from another ( Figure 4) . The SDRs are multimeric, non-metallo NAD(P)(H)-linked oxidoreductases (monomer molecular weight = 27 kDa). They are membrane-bound and often share <25% amino acid sequence identity, but available crystal structures show that disparate enzymes in this family have adopted identical protein folds. This fold has at its core a¯oret of 7b-strands with 3a-helices on either side of the strands ( Figure 5 ) and is clearly evident in the crystal structure of the estrogenic type 1 17b HSD Breton et al., 1996; Sawicki et al., 1999) . The cofactor lies across a Rossmann fold, the nicotinamide ring and the ribose moiety are in a syn-conformation, and these enzymes are B-face-speci®c in that they will transfer the pro-S hydride ion from the cofactor to the ketosteroid (Figure 6 ). They also contain a conserved catalytic motif of Tyr-X-X-(Ser)-Lys, where tyrosine is the catalytic general acid/base (Obeid and White, 1992; Chen et al., 1993; Puranen et al., 1994) . The bi-substrate reaction can display either ordered or random substrate binding, but when there is ordered binding the cofactor binds ®rst.
The AKRs are monomeric, NAD(P)(H)-linked oxidoreductases (molecular weight = 37 kDa) and are soluble. The steroidtransforming AKRs that fall into the AKR1C family share >67% amino acid sequence identity. Available crystal structures show that the AKRs adopt the (a/b) 8 -barrel or TIM-barrel motif in which there is an alternating array of a-helix and bstrand that repeats itself eight times. The b-strands make up the core of a barrel, at the back of which are three large loops (A, B and C) which de®ne steroid hormone speci®city (see Figure 5 ). These features are clearly evident in the crystal structures of the rat and human 3a-HSDs (Bennett et al., 1996; 1997; Jin et al., 2001; Nahoum et al., 2001) . The cofactor lies perpendicular to the steroid and is in an extended conformation in which the nicotinamide ring and the ribose are in the anti-conformation. The enzymes are A-face-speci®c and transfer the 4-pro-R hydride ion to the ketosteroid substrate. At the base of the barrel there is a catalytic tetrad that comprises Tyr55, Lys84, His117 and Asp50 (numbering according to rat 3a-HSD or AKR1C9) and where tyrosine is the catalytic general acid/base (Schlegel et al., 1998) . The similarity in the catalytic residues in SDRs and AKRs led to their superimposition, and this suggested that enzymes of both families have a conserved catalytic mechanism (Bennett et al., 1996) (Figure 6 ). In this mechanism, there is a direct hydride transfer from the cofactor to the 3-ketosteroid, which is then protonated by the catalytic tyrosine. This bi-substrate reaction in AKRs is strictly ordered where the cofactor must bind before steroid hormone binds to the active site.
Criteria to implicate HSDs in pre-receptor regulation of steroid hormone action A number of criteria have been established that must be ful®lled by all HSDs if they are to be involved in the prereceptor regulation of steroid hormone action. First, the HSD must function in a unidirectional manner; that is, it must act as a reductase or oxidase within a cellular context. Second, the HSD must be co-expressed with the steroid receptor that it is predicted to regulate. Third, the HSD and steroid receptor must be co-localized within the same cell type if the HSD is to effect intracrine modulation of the receptor. Fourth, HSDs should modulate trans-activation of steroid hormone receptors by their ligands in reporter gene assays; that is, HSDs should attenuate trans-activation of the receptor by active hormone or stimulate trans-activation of the receptor by inactive hormone (Figure 7) . Fifth, HSDs should show differential expression in hormonal dependent cancers; for example, AR-positive prostate cancer and ER-positive breast cancer. Sixth, inactivation of HSD isoforms by either targeted gene disruption, anti-sense oligonucleotides or small interfering RNA (si-RNA) should cause an altered steroid response at the receptor level.
Many HSDs, when characterized in vitro, behave as oxidoreductases and will freely interconvert steroid ketones with steroid alcohols. However, when they are transiently or stably transfected into null-environments they act predominantly as reductases or oxidases (Luu-The et al., 2001). It has been proposed that this may be predicted by their pyridine nucleotide preference. Those enzymes that prefer NADPH will act as reductases as they will use the major reductive cofactor in cells, whereas those that prefer NAD + will act as oxidases as they will use the major oxidative cofactor found in cells. This may be an oversimpli®cation however, as directionality will also be governed by the K eq for the forward and reverse reactions, and by the redox state that will govern the ratio of reduced versus oxidized pyridine nucleotide cofactor. Another powerful in¯uence may be product inhibition by the opposing cofactor. In recent experiments, the NADPHdependent reduction of 5a-DHT catalysed by AKR1C2 was found not to be affected by increasing concentrations of NAD + . By contrast, the NAD + -dependent oxidation of 3a-diol to 5a-DHT catalysed by AKR1C2 was potently inhibited by low (micromolar) concentrations of NADPH. This re¯ects the very tight binding of NADP(H)Ðwhich is a characteristic property of AKRsÐand suggests that these enzymes will function as reductases in a cellular context when low micromolar concentrations of NADPH prevail (Rizner et al., 2003a) .
Evidence that SDR isoforms regulate sex steroid hormone receptors
How well do SDRs that interconvert sex steroid hormones satisfy the criteria to regulate steroid hormone receptors? SDRs most implicated in regulating the ER are the type 1 and Type 2 17b-HSD 17-HSD/KSR2 HSD/17B2 >40.0 16q24 1-2 ER = estrogen receptor; HSD = hydroxysteroid dehydrogenase; 5a-DHT = 5a-dihydrotestosterone (17b-hydroxy-5a-androstane-3-one).
type 2/type 4 17b-HSDs. Transfection of type 1 17b-HSD into human embryonic kidney (HEK) cells showed that this enzyme acts almost exclusively as a reductase in a cellular context, producing 17b-estradiol (Labrie et al., 1997) . The enzyme is also highly overexpressed in mammary gland, and immunohistochemistry co-localizes the enzyme with ERa and ERb in human breast epithelial cells (Miettinen et al., 1996; Jarvinen et al., 2000) . The type 1 17b-HSD isoform was also elevated 20-fold in epithelial and stromal cells of human breast tumours (Spiers et al., 1998) . It displayed marked elevated expression in invasive lobular carcinoma by immunohistochemistry, and its overexpression correlated with the overexpression of aromatase (Sasano et al., 1996) . Although 17b-HSD, aromatase, ER and PR are co-expressed in mammary gland, a direct correlation between type 1 17b-HSD and ER expression has yet to be observed (Sasano et al., 1996) . By contrast, transfection of the type 2 17b-HSD into human embryonic kidney cells (HEK) 293 showed that this isoform preferentially oxidized 17b-estradiol back to estrone, and therefore this enzyme would eliminate estrogens in a cellular context (Wu Breton et al., 1996) . Panel B: a/b-barrel fold of an AKR. Panel C: loops A, B and C of an AKR (after Bennett et al., 1996 Bennett et al., ). et al., 1993 . Under these conditions, the K m for 17b-estradiol was 0.21 mM and the V max was 38 nmol oxidized/min/mg. Additionally, the type 4 17b-HSD catalysed the NAD + -dependent oxidation of 17b-estradiol with a K m <1.0 mM when expressed in the same cells, but the conversion rate was in pmol/min and a speci®c activity was not reported (Adamski et al., 1995) .
Other 17b-HSD isoforms which are SDRs may also be implicated in the control of ligand access to steroid receptors. 17b-HSD type 7 (prolactin receptor-associated protein) also catalyses the formation of 17b-estradiol and is expressed in the breast and prostate (Krazeisen et al., 1999) . Other 17b-HSD isoforms (types 8, 10 and 11), although important, are not expressed in breast and prostate cancer and are therefore unlikely to control ligand access to steroid receptors in these diseases.
Other SDRs implicated in regulating sex-steroid hormone receptors are the 11-cis-retinol-DH and RoDH/3a-HSD. These microsomal enzymes exhibit 3a-hydroxysteroid oxidase activity and convert 3a-diol to 5a-DHT (Biswas and Russell, 1997; Huang and Luu-The, 2001a) . Transfection studies showed that in HEK cells, 11-cis-retinol-DH will act almost exclusively as an oxidase (Huang and Luu-The, 2001a) . These enzymes are expressed in the prostate gland. Co-transfection of a pCMV-11-cis retinol-DH expression vector, a luciferase reporter gene construct driven by a prostate-speci®c antigen (PSA) promoter, and the human AR (as pCMV-hAR) showed that in the presence of 3a-diol expression from the PSA promoter was elevated 5-to 6-foldÐan effect that was abolished by 4-hydroxy-¯utamide (an AR antagonist) (Huang and Luu-The, 2001b) . This is the ®rst demonstration that a HSD can modulate trans-activation of a sex steroid receptor.
Based on the criteria that must be satis®ed to implicate SDRs in the regulation of sex steroid hormone receptors, the strongest case can be made for type 1 17b-HSD regulating the ER. However, experiments demonstrating that this isoform can regulate transactivation of the ER are lacking, and modulation of estrogen response using anti-gene or si-RNA targeting this HSD have yet to be performed.
Evidence that AKR isoforms regulate sex steroid hormone receptors
There are at least four human aldo-keto reductases that may be involved in regulating ligand access to nuclear receptors. These were originally identi®ed as 3a-HSD isoforms and correspond to: Figure 6 . Conserved reaction mechanism for HSDs. SDRs and AKRs use opposing faces of the nicotinamide ring (B or A, respectively) to deliver the hydride ion. Therefore, SDRs and AKRs catalyse pro-S and pro-R hydride transfers via identical mechanisms. A catalytic tyrosine and its interaction with a lysine residue is shown for simplicity. In AKRs, the catalytic tyrosine acts as a general base because its pK a is lowered by the lysine (oxidation direction), but it also acts a general acid because its pK b is increased by an adjacent histidine (reduction direction) (see Schlegel et al., 1998) . In SDRs, the catalytic tyrosine acts as a general base because its pK a is lowered by the lysine (oxidation direction), but it also acts as a general acid and the mechanism by which tyrosine assumes this role is uncertain. AKR1C1 20a(3a)-HSD; AKR1C2 (type 3 3a-HSD, and bile acidbinding protein); AKR1C3 (type 2 3a-HSD which is identical to type 5 17b-HSD); and AKR1C4 (type 1 3a-HSD) (Stolz et al., 1993; Khanna et al., 1995; Hara et al., 1996; Lin et al., 1997; Burczynski et al., 1998; Dufort et al., 1999) . Characterization of the recombinant enzymes showed that each isoform catalysed the reduction of 3-, 17-and 20-ketosteroids; and that each isoform catalysed the oxidation of 3a-, 17b-and 20a-hydroxysteroids to varying extents . Product pro®ling indicated that each isoform will reduce 5a-DHT to 3a-diol, D 4 -androstene-3,17-dione to testosterone, estrone to 17b-estradiol and progesterone to 20a-hydroxyprogesterone. Product pro®ling also indicated that each isoform will oxidize testosterone to D 4 -androstene-3,17-dione, 17b-estradiol to estrone and 20a-hydroxprogesterone to progesterone. Only one isoform, type 3 3a-HSD (bile acidbinding protein) was able to oxidize 3a-diol to 5a-DHT and is therefore a candidate enzyme to catalyse the back-reaction previously described. Combined AKR1C1±AKR1C4 catalyse the appropriate reactions to control ligand access to the AR, ER and PR .
The bimolecular rate constants (k cat /K m ) for 3-keto-, 17-ketoand 20-ketosteroid reduction and 3a-, 17b-and 20a-hydroxysteroid oxidation indicate that these AKR1C enzymes catalyse these reactions to varying extents. For example, AKR1C1 prefers to function as a 20a-HSD; AKR1C2 is a 3a-HSD with a low k cat /K m ; AKR1C3 prefers to act as a 17b-HSD; and AKR1C4 is a 3a-HSD with a high k cat /K m . How well do these enzymes satisfy the criteria to be involved in regulating ligand occupancy of steroid hormone receptors?
Transient transfection studies have addressed the directionality of AKR1C1±AKR1C3 in a cellular context. Transfection of AKR1C1 into COS-1 cells shows that this enzyme will reduce progesterone to 20a-hydroxyprogesterone, but the oxidation reaction is barely detectable (Zhang et al., 2000; T.L.Rizner and T.M.Penning, unpublished results) . Thus, the enzyme is tailored to eliminate progesterone. Transient transfection of AKR1C2 into HEK and COS-1 cells Rizner et al., 2003b) and stable expression of AKR1C2 into PC-3 cells shows that this enzyme will preferentially reduce 5a-DHT to 3a-diol, but that the reverse reaction is minor (Ji et al., 2003; Rizner et al., 2003a; . Whether this back-reaction can produce suf®cient 5a-DHT to activate the AR in a cellular context has yet to be determined.
Transient transfection of AKR1C3 into HEK cells showed that its preferred reaction was the reduction of D 4 -androstene-3,17-dione to testosterone. This activity was considered labile because the identical reaction was dif®cult to monitor in HEK cell lysates (Dufort et al., 1999) . By contrast, the bacterially expressed enzyme was stable Burczynski et al., 1998) . Thus, data are emerging which suggest that AKR1C1 will inactivate progesterone, AKR1C2 and AKR1C3 will inactivate 5a-DHT, while AKR1C3 can form testosterone in a cellular context.
The discrete tissue distribution of these AKR isoforms suggests that they may regulate steroid hormone action at the pre-receptor level. Quantitative isoform-speci®c RT-PCR showed that AKR1C2 and AKR1C3 are highly overexpressed in human prostate. Using cDNA probes for the coding region and the 3¢-UTR of AKR1C3, high expression was observed in primary epithelial cells from patients with benign hypertrophy of the prostate and prostate cancer, whereas expression in stromal cells was less . Although these probes cannot discriminate between AKR1C isoforms, they do indicate that they are more highly expressed in cells known to contain the AR.
Immunohistochemistry using a peptide-derived monoclonal antibody for AKR1C3 showed that this isoform is localized to the basal cells of the prostate and may provide a source of testosterone for the luminal cells to make 5a-DHT for the AR (ElAlfy et al., 1999) . RT-PCR also demonstrated high expression of AKR1C2 in human prostatic epithelial cells from prostate cancer patients, but expression is markedly attenuated in normal cells Rizner et al., 2003) . These data imply that AKR1C3 and AKR1C2 are expressed in regions of the prostate where they will control the local concentration of androgen available for the AR. The 17-ketosteroid reductase activity of AKR1C3 may contribute to the local production of testosterone, while the 3-ketosteroid reductase activities of AKR1C3 and AKR1C2 may lead to the elimination of 5a-DHT.
AKR1C3 is the most abundant AKR isoform expressed in human mammary epithelial cells when measured by RT-PCR . It has also been detected in these cells by immunohistochemistry using a peptide-derived antibody . Its unique product pro®ling suggests that it may contribute to a pro-estrogenic state in the breast. This enzyme will reduce estrone to 17b-estradiol; and it will reduce D 4 -androstene-3,17-dione to testosterone, which can then be aromatized to 17b-estradiol by CYP arom. AKR1C3 can also reduce progesterone to the inactive progestin (20a-hydroxyprogesterone). When these reactions are combined, AKR1C3 might be responsible for the unopposed actions of estrogens in the breast.
More still needs to be done to characterize the role of AKR1C1 in progesterone action. One hypothesis is that AKR1C1 plays a role in diseases of the endometrium. Endometriosis and endometrial cancer are both diseases that may arise due to the action of estrogens when unopposed by progestins (Attia et al., 2000; Arnett-Mans®eld et al., 2001; Bulun et al., 2002; Chwalisz et al., 2002; Rice, 2002) . In the normal female, this could occur if there were a decrease in PR expression and/or an increase in the elimination of progesterone at the target tissue. In this instance, overexpression of AKR1C1 in these diseases might be anticipated.
Co-localization of AKR1C1±AKR1C3 with the PR, AR and ERa and ERb in different target tissues has yet to be performed systematically. In addition, the ability of these enzymes to modulate the trans-activation of the AR, ER and PR using reporter gene constructs is yet to be elucidated. The murine homologues of these AKR1C enzymes have as yet not been completely identi®ed; therefore, the generation of AKR1C null/mice has not been attempted. Thus, much needs to be done to validate the role of AKR1C isoforms in the pre-receptor regulation of steroid hormone action.
Development of SIMs
HSDs which are SDRs and AKRs are clearly potential drug targets. Development of SIMs requires validation of the target, and the most important targets in the SDR superfamily would appear to be 11b-HSD type 1 and type 2 and estrogenic type 1 17b-HSD. There is suf®cient validation of these targets to warrant inhibitor design. Inhibitors of type 1 11b-HSD would prevent cortisone conversion to cortisol and could be used to control visceral obesity. Alternatively, inhibitors of type 2 11b-HSD would enhance mineralocorticoid activity and would provide a method of treating hypotension. Progress towards these inhibitors will not be discussed since the emphasis of this review is on HSDs and their pre-receptor regulation of sex steroid receptors.
Emphasis has been placed on the development of steroid-based inhibitors of estrogenic type 1 17b-HSD based on three strategies. These include the development of mechanism-based inactivators (Penning and Ricigliano, 1991; Penning, 1994) , the synthesis of bifunctional ligands, that will inhibit 17b-HSD and antagonize ERa (Labrie et al., 1992) , and bi-substrate analogues which contain portions of both the steroid and cofactor substrates (Qiu et al., 2002) (Figure 8 ). Mechanism-based inactivators are substrate mimics which are innocuous by themselves but require transformation by the target enzyme to an electrophilic species that will cause enzyme inactivation via alkylation. A series of latent Michael-acceptors were designed which all involved the enzymecatalysing conversion of a steroid alcohol to yield an a,bunsaturated ketone which would then covalently modify the target. The problem with this approach was that the reactive species is produced as a result of oxidation when, in a cellular context, type 1 17b-HSD prefers to function as a reductase. This area was recently reviewed (Penning, 1996) .
Bifunctional ligands have been developed with the knowledge that the ER is best antagonized when there is a large substituent on the B-ring and 17b-HSD will tolerate substituents at the 16a-position. A series of compounds which was developed to meet these criteria included 7a-alkylamide 16a-halogenated estradiol (E 2 ) analogues (EM-139) (Labrie et al., 1992) and 6b-butylmethylalkylamides (Poirier et al., 1998) .
Bi-substrate analogues have been designed which contain portions of both substrates. Thus, hybrids of 17b-estradioladenosine have been synthesized and evaluated (Qiu et al., 2002) . EM-1745, which contained a linker of 8-methylene groups between the two moieties, was found to be a potent competitive inhibitor of type 1 17b-HSD (K i = 3.0 nM). A crystal structure of the 17b-HSD´EM-1745 binary complex, obtained at 1.6 A Ê provided atomic resolution of the strong interactions that occur between the bi-substrate analogue with the steroid and cofactor binding sites of the enzyme (Qiu et al., 2002) .
Potential drug targets in the AKR1C family would be AKR1C1, AKR1C2 and AKR1C3. Inhibitors of AKR1C1 could prevent progesterone metabolism, and help maintain pregnancy. Inhibition of AKR1C3 may be important to prevent the local formation of testosterone in the prostate and the formation of a pro-estrogenic state in the breast. Two approaches are being exploited. One involves the development of steroid carboxylates, while the other is based on nonsteroidal anti-in¯ammatory drug (NSAID) analogues. Steroid carboxylates are desirable because the active site is characterized by an oxyanion hole that has (TyrOH 2 + ) character (Jin et al., 2001) . Also, although AKR1C1 and AKR1C2 differ by seven amino acids only the latter is potently inhibited by bile acids (C-24 carboxylates) yielding IC 50 values in the nanomolar range (Hara et al., 1996) . These ®ndings indicate the requirement for steroid carboxylates as inhibitors and indicate that discrimination between AKR1C isoforms can be achieved.
NSAID analogues are desirable for several reasons. First, classical NSAIDs have been found potently to inhibit AKR1C isoforms in rank-order of their anti-in¯ammatory potency (Penning and Talalay, 1983) . Second, classical NSAIDs all contain carboxylate functionalities which should tether the analogues to the catalytic tyrosine. Third, N-phenylanthranilic acid, 1-methyl-pyrrole acetic acids and arylpropionic acids can be made by simple coupling chemistries so that a large number of analogues are either available or can be synthesized by combinatorial means (Acheson, 1973; Scherrer and Beatty, 1980) . Fourth, an examination of the structure±activity relationships for classical NSAIDs indicates which substituents abolish their ability to inhibit prostaglandin H synthase, providing important leads to inhibitors that can distinguish between AKR1C isoforms and prostaglandin H synthase.
Conclusions
It is hypothesized that HSDs regulate steroid hormone action at the pre-receptor level. Enzymes exist that may regulate the AR, ER and PR occupancy and their trans-activation. Each enzyme requires further validation as a drug target. Currently, the most convincing evidence is that the type 1 17b-HSD can regulate ER and is therefore a drug target. These HSDs belong to two protein superfamilies, the SDRs and the AKRs, and available crystal structures for enzymes of both families suggest that rationale design of isoform selective inhibitors should be possible.
